NCT07423429Recruiting
Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration
Retrospective Multicenter Real-world Observational Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration
Source: ClinicalTrials.gov · Last updated 25 Jun 2026
Brief summary (registry, in English)
Age-related macular degeneration is a leading cause of visual impairment in older adults. In its exudative form, repeated intravitreal injections of anti-VEGF agents are required to control disease activity. A new formulation of aflibercept at a higher dose (8 mg) has been developed with the aim of extending the interval between injections. This multicenter retrospective real-world observational study will evaluate the effect of switching to aflibercept 8 mg in patients with refractory or dependent exudative age-related macular degeneration. Clinical data collected during routine care will be analyzed to compare injection intervals, treatment burden, visual outcomes, anatomical outcomes, and safety before and after the switch.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 13 Feb 2026
- Start date
- 20 Feb 2026
- Primary completion date
- 20 Oct 2026
- Lead sponsor
- Nantes University Hospital
- Diseases
- Macular degeneration
- NCT number
- NCT07423429
What you commit to
- Study type: Observational
- Planned participants: 100
- From 20 Feb 2026 to the primary completion date, 20 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of diabetic macular edema
- History of uveitis
- History of retinal vein occlusion (branch or central)
- History of pseudovitelliform macular dystrophy
Other
- High myopia (axial length \> 26 mm or spherical equivalent \< -6 diopters)
- Angioid streaks
- Moderate or severe diabetic retinopathy
- Patient under legal guardianship or curatorship
- Pregnant or breastfeeding women
Who the study is looking for
- Adults (≥18 years) with exudative (neovascular) age-related macular degeneration
- Treated with intravitreal anti-VEGF therapy for more than 1 year
- Switched to aflibercept 8 mg before July 31, 2025
- Injection interval strictly less than 12 weeks prior to switch
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Nantes - Ophthalmology Department Coordinator of this site? Confirm its status | Nantes | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.